From Discovery to Smart Pens The History of NAD Plus and Its Modern Use
NAD+ may feel like a recent wellness topic, but the molecule has been part of biochemistry for more than a century. Scientists first encountered it while studying yeast fermentation. Later, they recognized it as a central carrier of energy in cells. Decades after that, researchers found that cells also use NAD+ in DNA repair, stress responses, calcium signaling, and gene regulation.
That long history matters because modern NAD-related products sit on top of several different kinds of evidence. Some functions of NAD+ are basic, established biology. Some research is promising but still early. Some commercial applications are widely available, while their clinical benefits remain under study.
This article follows the history of NAD+ in order, from the laboratory bench to oral supplements, IV services, injection devices, and modern smart pens.
The story begins with yeast fermentation
The history of NAD+ starts in the early 1900s, when biochemists were trying to understand how yeast converted sugar into alcohol.
In 1906, British scientists Arthur Harden and William John Young reported that yeast juice needed a small, heat-stable, dialyzable substance for fermentation to proceed. They called it a “coferment.” Their work helped establish that enzymes did not act alone. Small helper molecules could be essential to metabolism.
At the time, no one called the substance NAD+. The molecule’s name, structure, and biological role came later. The early finding was still a turning point. It showed that cells relied on chemical partners that could move between enzymes and carry out repeated reactions.
Harden later shared the 1929 Nobel Prize in Chemistry with Hans von Euler-Chelpin for work on sugar fermentation and fermentative enzymes. That recognition reflected how important fermentation research had become to the birth of modern biochemistry.
Scientists identify NAD+ as a redox coenzyme
By the 1930s, researchers had a clearer picture. The molecule first observed as a coferment was part of a larger family of compounds known as pyridine nucleotides.
In 1936, Otto Warburg and Walter Christian described the role of pyridine nucleotide coenzymes in hydrogen transfer reactions. NAD+ was then often called DPN, short for diphosphopyridine nucleotide. Its close relative NADP+ was called TPN, or triphosphopyridine nucleotide.
The modern name, nicotinamide adenine dinucleotide, describes its structure. NAD+ contains:
Nicotinamide, a form related to vitamin B3
Adenine, one of the bases also found in DNA and RNA
Two nucleotide units connected through phosphate groups
Its key job in energy metabolism is to cycle between two forms:
Molecule | Simple explanation | Main role |
NAD+ | The oxidized form | Accepts electrons and hydrogen during metabolism |
NADH | The reduced form | Carries those electrons to help produce ATP |
NR and NMN | Precursors | Building blocks cells can use to make NAD+ |
A useful analogy is a rechargeable carrier. NAD+ is the empty carrier, ready to pick up electrons. NADH is the loaded carrier, bringing those electrons to systems that help make cellular energy.
That does not mean NAD+ is “energy” itself. Rather, it helps cells transfer energy from nutrients into usable chemical form.
NAD+ becomes central to cellular energy metabolism
As biochemistry advanced, NAD+ became recognized as one of the cell’s most important redox coenzymes.
In glycolysis, the tricarboxylic acid cycle, and mitochondrial respiration, NAD+ accepts electrons from nutrient breakdown. NADH then donates electrons to the respiratory chain, supporting ATP production. ATP is the chemical currency cells use for many forms of work, from muscle contraction to molecular repair.
This role is established biology. It appears across textbooks, laboratory methods, and decades of primary research.
NAD+ also connects nutrition to metabolism. In 1937, Conrad Elvehjem and colleagues showed that nicotinic acid and nicotinamide could prevent or treat black tongue in dogs, a pellagra-like condition. This work helped identify niacin, or vitamin B3, as a nutrient linked to NAD+ biology.
In humans, severe niacin deficiency causes pellagra, classically associated with dermatitis, diarrhea, dementia, and, if untreated, death. Treating deficiency with niacin is an established medical use. That is different from claiming that extra NAD+ or NAD precursors improve health in people who are not deficient.
The distinction is important. A molecule can be essential for life without every attempt to raise it producing a proven clinical benefit.
NAD+ research expands beyond energy
For much of the 20th century, NAD+ was known mainly for metabolism. Then researchers began to uncover another side of the molecule. Cells do not only use NAD+ as an electron carrier. They also consume it in signaling reactions.
DNA repair and PARP enzymes
In the 1960s, research by Pierre Chambon, Paul Mandel, and colleagues helped establish that cells could use NAD+ to build poly(ADP-ribose), a chain-like molecule involved in DNA damage responses. The enzymes now known as PARPs, or poly(ADP-ribose) polymerases, use NAD+ as a substrate.
This area became highly important in cancer biology. PARP inhibitors are now clinically used in certain cancers with DNA repair defects. That clinical success does not mean NAD+ products treat cancer. It shows that NAD+-consuming pathways are biologically and medically significant.
Calcium signaling and cyclic ADP-ribose
In 1989, Hon Cheung Lee and colleagues reported cyclic ADP-ribose as a calcium-mobilizing messenger. This work added another layer to NAD+ biology. NAD-derived molecules help cells control calcium signals, which affect secretion, contraction, nerve activity, and other processes.
Sirtuins and cellular regulation
Around 2000, Shin-ichiro Imai, Leonard Guarente, and colleagues showed that Sir2 proteins function as NAD+-dependent deacetylases. These proteins, now called sirtuins, linked NAD+ to gene regulation, stress responses, and aging research.
This discovery helped drive public interest in NAD+. Laboratory studies in yeast, worms, flies, and mice suggested that NAD+ metabolism could influence lifespan-related pathways. These findings were important, but they should not be overstated. Animal and cell studies do not automatically become proven human anti-aging outcomes.
NR and NMN bring precursor research into focus
If NAD+ is essential, a practical question follows. How do cells make it?
Cells can produce NAD+ through several routes. They can use dietary tryptophan, nicotinic acid, nicotinamide, and other vitamin B3-related molecules. Two modern precursors receive the most public attention:
Nicotinamide riboside
NR is a form of vitamin B3. In 2004, Charles Brenner and colleagues identified NR as a NAD+ precursor through a dedicated kinase pathway in yeast, with relevance to broader NAD+ metabolism. Human studies have shown that oral NR can raise NAD-related metabolites in blood. Evidence for specific disease prevention or broad wellness outcomes remains more limited.
Nicotinamide mononucleotide
NMN is one step closer to NAD+ in some biosynthetic routes. Animal studies have reported effects on metabolism, vascular function, and age-related biology. Human trials have begun to examine safety, blood markers, and selected functional outcomes. Results are still developing, and findings from mice should not be treated as confirmed human benefits.
The main point is simple. Precursors are not the same as NAD+ itself. They are ingredients cells may convert into NAD+ through enzyme-controlled pathways. The degree of conversion, tissue distribution, dosing, and clinical meaning can vary.
Modern NAD-related products and services
Public awareness of NAD+ has grown because several product categories have become commercially available. Popularization here means more visibility, more consumer access, and more discussion. It does not mean universal adoption or proven effectiveness for every claim.
Oral products
Oral NAD-related products include NR, NMN, niacin, nicotinamide, and formulations marketed as NAD+. Oral products are generally easier to use and more scalable than clinical administration.
The evidence differs by ingredient. Niacin has established roles in deficiency treatment and, at drug-level dosing, lipid management under medical care. NR and NMN have human data showing changes in NAD-related blood markers in some studies. Clinical outcomes such as improved longevity, broad anti-aging effects, or disease prevention are not established.
Regulatory status also differs. In the United States, dietary supplements are regulated differently from drugs. They cannot legally claim to diagnose, treat, cure, or prevent disease without drug approval.
Intravenous NAD+
IV NAD+ services deliver NAD+ directly into the bloodstream, usually in wellness clinic settings. This route bypasses digestion, but it raises separate questions about dosing, monitoring, tolerability, sterility, and medical oversight.
Some clinics market IV NAD+ for fatigue, recovery, aging, or addiction support. The strength of evidence varies, and many claims remain under-studied. IV administration should be performed only by qualified professionals in settings that follow applicable medical and compounding standards.
Injection devices and smart pens
Injection formats aim to make administration more controlled and portable. Depending on the product, these may involve prescription status, compounded formulations, device rules, training requirements, and local regulations.
A smart pen adds another layer. It may support dose tracking, portability, reminders, or digital traceability. These features can improve record-keeping and user experience, but they do not by themselves prove a health outcome.
This article is for educational purposes only and is not medical advice. Any NAD-related therapy should be discussed with a qualified health professional, especially for people with medical conditions, pregnancy, medication use, or planned procedures.
What is known and what is still emerging
The history of NAD+ shows why careful language matters.
Well established
NAD+ and NADH are central to redox metabolism.
NAD+ is required for many cellular enzymes.
Vitamin B3 deficiency can cause serious disease.
NAD+ is consumed by PARPs, sirtuins, and other enzymes.
Promising but still developing
Whether raising NAD+ improves specific outcomes in generally healthy humans
Which precursor, dose, and route matters most
How blood NAD markers relate to tissue NAD levels
Whether long-term use changes meaningful clinical endpoints
Not proven by current evidence
That NAD+ products reverse human aging
That animal lifespan findings directly apply to people
That IV or injection routes are automatically superior to oral precursors
That smart delivery devices prove therapeutic benefit on their own
The research field is active for good reason. NAD+ sits at the intersection of metabolism, repair, and cell signaling. That makes it scientifically important. It also makes it easy for marketing to run ahead of clinical evidence.
NADVE’s place in the modern NAD+ chapter
The modern phase of NAD+ is not only about the molecule. It is also about format, usability, data, and responsible design.
NADVE focuses on NAD+ Smart Pen development with attention to portability, user-centered design, and digital traceability. A smart pen can help support structured administration records, product handling visibility, and a more controlled experience compared with less traceable formats.
That design focus should be understood clearly. NADVE’s interest in smart delivery technology does not imply that the device has demonstrated anti-aging benefits. The stronger claim is also the more responsible one: as NAD-related products become more visible, better design and traceability can help raise standards around how they are used, tracked, and discussed.
References
Arthur Harden and William John Young, 1906, early work on yeast fermentation and coferment, Proceedings of the Royal Society B
Nobel Prize, 1929 Chemistry Prize to Arthur Harden and Hans von Euler-Chelpin, NobelPrize.org
Otto Warburg and Walter Christian, 1930s work on pyridine nucleotide coenzymes, summarized in Nobel resources on Warburg’s biochemical research, NobelPrize.org
Conrad Elvehjem and colleagues, 1937, niacin and pellagra-related research, historical overview from the National Institutes of Health Office of Dietary Supplements
Hon Cheung Lee and colleagues, 1989, cyclic ADP-ribose and calcium signaling, Nature
Shin-ichiro Imai, Cynthia Armstrong, Matt Kaeberlein, and Leonard Guarente, 2000, NAD-dependent Sir2 deacetylase activity, Nature
Pawel Bieganowski and Charles Brenner, 2004, nicotinamide riboside as a NAD+ precursor, Cell
Samuel Trammell and colleagues, 2016, oral nicotinamide riboside and human NAD+ metabolism, Nature Communications
Christopher Martens and colleagues, 2018, chronic nicotinamide riboside supplementation in middle-aged and older adults, Nature Communications
Masataka Yoshino and colleagues, 2021, NMN and muscle insulin sensitivity in prediabetic women, Science
Comments